Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. News
  7. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Real-time Estimate Cboe BZX  -  11:12 2022-11-30 am EST
2.100 USD   -4.11%
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Development Projects
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

09/12/2022 | 07:15am EST

Invivyd, formerly Adagio Therapeutics announced that the Company has generated multiple next-generation candidate antibodies for the prevention and treatment of COVID-19, including two molecules designated for near-term clinical development in combination as NVD200. NVD200 is expected to enter the clinic in the first quarter of 2023. The integrated Invivyd discovery platform generated dozens of potent and broadly neutralizing anti-SARS-CoV-2 monoclonal antibody candidates over the past two quarters.

Now included in Invivyd's pipeline are multiple novel discovery-stage molecules that were produced using the company's deep expertise at the intersection of evolutionary virology, predictive modeling, and antibody engineering. These molecules are all designed to be high-functioning and long-lasting with a high barrier to viral escape. The company's antibody candidates are tuned to optimize across potency, breadth of neutralization, barrier to escape, and half-life.

Such antibodies may be deployed prior to exposure to SARS-CoV-2 to prevent disease or, once sick, to treat disease. NVD200 is a combination of two monoclonal antibodies which demonstrated potent in vitro neutralizing activity against prior and current SARS-CoV-2 variants of concern, including Omicron BA.1, BA.2, BA.4, BA.5, and BA.2.75 sublineages, as well as the more antigenically divergent SARS-CoV-1. This antibody combination has been selected for neutralization potency, breadth of coverage, and non-dominant epitope recognition. The antibodies in the combination target non-overlapping epitopes that are rarely targeted by endogenous neutralizing antibodies, which limits immune pressure on these sites and increases the probability of sustained utility in an evolving viral landscape.

One of the antibodies in the combination is a re-engineered version of adintrevimab, the company's most advanced product candidate, which met all primary endpoints with statistical significance in a pre-Omicron setting in global Phase 3 clinical trials for the prevention and treatment of COVID-19. Invivyd's platform includes continuous variant monitoring and extensive exploration of the vast universe of potential antibodies outside of the common human immune repertoire. The company has already identified hundreds of neutralizing monoclonal antibodies and selected them based on stringent selection criteria including potency, breadth of coverage across SARS-CoV-2 variants and other sarbecoviruses, immunorecessive epitope targeting, and specified developability criteria.


ę S&P Capital IQ 2022
All news about INVIVYD, INC.
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Develo..
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
GL
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
CI
11/10INVIVYD, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Transcript : Invivyd, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/10Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
GL
11/09Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
GL
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -236 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -1,01x
Yield 2022 -
Capitalization 239 M 239 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 102
Free-Float 72,5%
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 2,19 $
Average target price 3,83 $
Spread / Average Target 75,0%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Frederick W. Driscoll Chief Financial & Accounting Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.-69.83%239
VERTEX PHARMACEUTICALS44.05%81 199
REGENERON PHARMACEUTICALS, INC.17.41%78 615
BIONTECH SE-36.54%39 760
WUXI APPTEC CO., LTD.-34.05%31 776
GENMAB A/S20.91%28 866